1. QED Therapeutics. QED Pipeline. 2021. https://www.qedtx.com/our-product/#pipeline. Accessed 29 Jun 2021.
2. QED Therapeutics. TRUSELTIQ (infigratinib) capsules, for oral use: US prescribing information. 2021. https://www.accessdata.fda.gov. Accessed 29 Jun 2021.
3. US Food & Drug Administration. FDA grants accelerated approval to infigratinib for metastatic cholangiocarcinoma [media release]. 28 May 2021. https://www.fda.gov.
4. BridgeBio Pharma. BridgeBio Pharma licenses late-stage oncology drug infigratinib to tackle FGFR-driven maladies; establishes new subsidiary QED Therapeutics with $65 million in initial financing [media release]. 30 Jan 2018. http://www.bridgebio.com.
5. The Ivy Brain Tumor Center. Ivy Brain Tumor Center and BridgeBio subsidiary QED Therapeutics announce collaboration to advance cancer research and treatment options [media release]. 24 Sep 2019. http://www.ivybraintumorcenter.org.